Esketamine - Search News

FDA, major depressive disorder and Esketamine

Hosted on MSN · 2d

FDA Expands Approval of Esketamine for Depression

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral antidepressants, maker Johnson & Johnson announced on Tuesday.

The American Journal of Manage… · 2d

Esketamine Approved by FDA as First Monotherapy for Treatment-Resistent Depression

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

Popular Science · 1d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

23hon MSN

TTUHSC Psychiatry chairman discusses newly approved antidepressant nasal spray

The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...

2don MSN

J&J wins label expansion for depression therapy Spravato

Johnson & Johnson (NYSE:JNJ) announced Tuesday that the U.S. FDA approved a supplemental New Drug Application for its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results